These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 2790325

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH.
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [Abstract] [Full Text] [Related]

  • 3. Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.
    Sykes M.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():30-3. PubMed ID: 2534057
    [Abstract] [Full Text] [Related]

  • 4. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M, Sharabi Y, Sachs DH.
    Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect.
    de la Selle V, Miconnet I, Gilbert D, Bruley-Rosset M.
    Bone Marrow Transplant; 1995 Jul; 16(1):111-8. PubMed ID: 7581109
    [Abstract] [Full Text] [Related]

  • 9. Alloengraftment in IL-2-treated mice.
    Sykes M, Pearson DA.
    Bone Marrow Transplant; 1992 Aug; 10(2):157-63. PubMed ID: 1525605
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of the anti-GVHD effect of IL-2. I. Protective host-type cell populations are not induced by IL-2 treatment alone.
    Abraham VS, Sykes M.
    Bone Marrow Transplant; 1991 Aug; 7 Suppl 1():29-32. PubMed ID: 2043882
    [Abstract] [Full Text] [Related]

  • 11. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL, Atasoylu AA.
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [Abstract] [Full Text] [Related]

  • 12. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
    Sykes M, Chester CH, Sundt TM, Romick ML, Hoyles KA, Sachs DH.
    J Immunol; 1989 Dec 01; 143(11):3503-11. PubMed ID: 2584703
    [Abstract] [Full Text] [Related]

  • 13. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 14. Effects of T cell depletion in radiation bone marrow chimeras. II. Requirement for allogeneic T cells in the reconstituting bone marrow inoculum for subsequent resistance to breaking of tolerance.
    Sykes M, Sheard MA, Sachs DH.
    J Exp Med; 1988 Aug 01; 168(2):661-73. PubMed ID: 3045249
    [Abstract] [Full Text] [Related]

  • 15. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 01; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 16. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD, McCabe C, Hanke CA, Truitt RL.
    J Immunol; 1995 May 15; 154(10):5542-54. PubMed ID: 7730653
    [Abstract] [Full Text] [Related]

  • 17. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 15; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P, Vourka-Karussis U, Weiss L, Slavin S.
    J Immunol; 1993 Nov 01; 151(9):4803-10. PubMed ID: 8409438
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
    Sykes M, Eisenthal A, Sachs DH.
    J Immunol; 1988 May 01; 140(9):2903-11. PubMed ID: 2966200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.